Rapid policy statement: Ruxolitinib for chronic Graft versus Host Disease

The most common treatment option for corticosteroid-refractory graft versus host disease is extracorporeal photopheresis. Ruxolitinib provides an alternative option which can be taken at home, and this document sets out recommendations for its use in the context of Covid-19.

SPS commentary:

Ruxolitinib does not have a European Medicines Agency license for graft versus host disease (GvHD), but it is approved in the US for acute GvHD. Appendix 1 summarises the evidence considered (a retrospective survey of outcomes and two retrospective case series).

NHS England